Price T Rowe Associates Inc. MD Sells 442,601 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Price T Rowe Associates Inc. MD decreased its position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 95.7% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 19,918 shares of the company's stock after selling 442,601 shares during the period. Price T Rowe Associates Inc. MD's holdings in ARS Pharmaceuticals were worth $211,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC raised its stake in shares of ARS Pharmaceuticals by 93.1% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 344,171 shares of the company's stock worth $3,631,000 after purchasing an additional 165,950 shares in the last quarter. Wells Fargo & Company MN raised its stake in shares of ARS Pharmaceuticals by 47.1% during the 4th quarter. Wells Fargo & Company MN now owns 41,701 shares of the company's stock worth $440,000 after purchasing an additional 13,361 shares in the last quarter. Peregrine Capital Management LLC bought a new stake in shares of ARS Pharmaceuticals during the 4th quarter worth approximately $4,469,000. Vanguard Group Inc. raised its stake in shares of ARS Pharmaceuticals by 3.5% during the 4th quarter. Vanguard Group Inc. now owns 3,464,952 shares of the company's stock worth $36,555,000 after purchasing an additional 115,656 shares in the last quarter. Finally, MetLife Investment Management LLC raised its stake in shares of ARS Pharmaceuticals by 12.9% during the 4th quarter. MetLife Investment Management LLC now owns 33,086 shares of the company's stock worth $349,000 after purchasing an additional 3,769 shares in the last quarter. Institutional investors own 68.16% of the company's stock.

ARS Pharmaceuticals Stock Up 2.1%

Shares of SPRY stock traded up $0.30 during trading on Thursday, reaching $14.52. 875,775 shares of the company's stock were exchanged, compared to its average volume of 1,245,688. The stock has a market capitalization of $1.43 billion, a PE ratio of -28.47 and a beta of 0.84. ARS Pharmaceuticals, Inc. has a twelve month low of $7.55 and a twelve month high of $18.51. The firm's fifty day moving average price is $13.54 and its 200-day moving average price is $12.87.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.35). The business had revenue of $7.97 million for the quarter, compared to analyst estimates of $7.48 million. As a group, analysts anticipate that ARS Pharmaceuticals, Inc. will post -0.55 EPS for the current fiscal year.

Insider Buying and Selling

In other ARS Pharmaceuticals news, Director Brent L. Saunders sold 120,000 shares of the company's stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $14.25, for a total value of $1,710,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Alexander A. Fitzpatrick sold 102,969 shares of the company's stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $14.10, for a total value of $1,451,862.90. Following the completion of the transaction, the insider now directly owns 89,613 shares in the company, valued at approximately $1,263,543.30. This represents a 53.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 382,571 shares of company stock valued at $5,177,904. 33.50% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on SPRY shares. William Blair reiterated an "outperform" rating on shares of ARS Pharmaceuticals in a research note on Monday, March 3rd. Scotiabank started coverage on ARS Pharmaceuticals in a research note on Friday, March 7th. They set a "sector outperform" rating and a $30.00 price objective on the stock. Wall Street Zen cut ARS Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Thursday. Finally, Oppenheimer assumed coverage on ARS Pharmaceuticals in a research note on Monday, February 10th. They set an "outperform" rating and a $40.00 price objective on the stock. One analyst has rated the stock with a sell rating, five have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $31.00.

ARS Pharmaceuticals Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.